



C9088

HOPD, ASC: Separate Payment Through 2027 (Medicare)

REIMBURSEMENT AND BILLING GUIDE

For billing and coding questions, call **Heron Connect®** at **1-844-HERON11 (1-844-437-6611)** 8 AM to 5 PM ET, Monday through Friday.

ZYNRELEF is the first and only extended-release dual-acting local anesthetic.

INDICATION

ZYNRELEF is indicated in adults for instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.

Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

- Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
- ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
- NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

See Important Safety Information throughout and full [Prescribing Information](#), including **Boxed Warning**.

INTRODUCTION

Heron Therapeutics, Inc, is pleased to provide this reference guide to support patient access to ZYNRELEF.

The coding information contained herein is for informative purposes only and is not a guarantee of coverage or reimbursement for any product or service. This information is not intended to substitute for the physician's independent diagnosis or treatment of each patient.

Coding, coverage, and reimbursement for ZYNRELEF will vary based on the patient's health insurance and the reimbursement status per site of care.

HERON CONNECT

Dedicated Heron Connect Reimbursement Counselors offer customized support for ZYNRELEF billing and coding questions. Reimbursement Counselors are available at **1-844-HERON11 (1-844-437-6611)** from 8 AM to 5 PM ET, Monday through Friday.

For more information, visit [HeronConnect.com](https://www.HeronConnect.com)



IMPORTANT SAFETY INFORMATION (CONT)

Contraindications

ZYNRELEF is contraindicated in patients with a known hypersensitivity (eg, anaphylactic reactions and serious skin reactions) to any amide local anesthetic, NSAIDs, or other components of ZYNRELEF; with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients); undergoing obstetrical paracervical block anesthesia; or undergoing CABG.

Warnings and Precautions

Dose-Related Toxicity: Monitor cardiovascular and respiratory vital signs and patient's state of consciousness after application of ZYNRELEF. When using ZYNRELEF with other local anesthetics, overall local anesthetic exposure must be considered through 72 hours

Hepatotoxicity: If abnormal liver tests persist or worsen, perform a clinical evaluation of the patient

Hypertension: Patients taking some antihypertensive medication may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.

Heart Failure and Edema: Avoid use of ZYNRELEF in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.

See Important Safety Information throughout and full [Prescribing Information](#), including [Boxed Warning](#).

ZYNRELEF REIMBURSEMENT AND BILLING SUMMARY

ZYNRELEF should be billed using C9088. The billable unit for C9088 is 1 mg/0.03 mg.

Medicare Billing and Reimbursement

- ZYNRELEF is reimbursed separately in HOPDs and ASCs **through 2027**
- **Through March 2025:** ZYNRELEF is separately reimbursed at **ASP + 6%** in HOPDs and ASCs under 3-year transitional pass-through status
- **Effective April 1, 2025:** ZYNRELEF is covered under the Non Opioid Policy for Pain Relief.*

The Policy provides separate payments for qualifying non-opioid treatments for pain relief in both the hospital outpatient department and ambulatory surgical center settings. The goal of this policy is to remove financial barriers to use non-opioids and ensure the use of opioids is not financially incentivized.

Commercial Billing and Reimbursement

- Commercial payers have been notified that C9088 has been assigned for ZYNRELEF; many customers have reported separate commercial payment
- Commercial reimbursement varies by payer and site of care; contact payers to verify coverage
- Heron offers resources to assist with billing and coding and to support separate payment requests

*The key inclusion criteria are the following:

- A label indication approved by the Food and Drug Administration to reduce postoperative pain, or produce postsurgical or regional analgesia, without acting upon the body's opioid receptors.
- Demonstrated the ability to replace, reduce, or avoid intraoperative or postoperative opioid use or the quantity of opioids prescribed in a clinical trial or through data published in a peer-reviewed journal.

ZYNRELEF Coding Information

HCPCS Code	Description	Billable Unit
C9088	Instillation, bupivacaine and meloxicam	1 mg/0.03 mg

NDC ^a	Bupivacaine/Meloxicam	Billable Units ^b
47426-303-01 (VVS)	200 mg/6 mg	200
47426-501-02 (VAN)	400 mg/12 mg	400
47426-503-01 (VAN)	200 mg/6 mg	200

^a11-digit NDCs for billing ZYNRELEF include a 0 before the 3 of the product code.

^bUse the JZ modifier if there are no discarded amounts. Use the JW modifier to separately bill unused and discarded drug amounts.

Note: ZYNRELEF is supplied as a kit consisting of a single-dose nonsterile glass vial (containing sterile active ingredients) and the following sterile components: Luer lock syringe(s), a vented vial spike, Luer lock cone-shaped applicator(s), and syringe tip cap(s). ZYNRELEF should only be prepared and administered with the components provided in the ZYNRELEF kit.

Modifier	Description
JZ	Zero drug amount discarded/not administered to any patient
JW	Drug amount discarded/not administered to any patient (indicate quantity discarded)
JG	Modifier for drug or biological acquired with 340B drug pricing program discount, reported for informational purposes
TB	Modifier for drug or biological acquired with 340B drug pricing program discount; reported for informational purposes for select entities

Note: For dates of service on or after July 1, 2023, the JZ modifier is required on claims for single-dose containers when no amount was discarded.

IMPORTANT SAFETY INFORMATION (CONT)

Warnings and Precautions (cont)

Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ZYNRELEF in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal failure.

See Important Safety Information throughout and full [Prescribing Information](#), including [Boxed Warning](#).

ASC COVERAGE AND BILLING FOR ZYNRELEF

Coverage for ZYNRELEF varies by health insurance plan and site of care. The table below summarizes the coverage and payment type for ASCs.

ZYNRELEF Coverage and Reimbursement Policy in ASCs

Medicare	ZYNRELEF is reimbursed separately through 2027 . Through March 2025: Separate reimbursement at ASP + 6% (<i>pass-through status</i>). April 2025 through December 2027: Separate reimbursement under law promoting access to non-opioids (<i>HR 2617 §4135, signed December 2022</i>).
Medicaid	Each State Medicaid Agency sets its own coverage policies and payment rates.
Private Commercial Payer	Separate payment for ZYNRELEF is available for many commercial patients. Commercial reimbursement varies by payer and site of care; contact payers to verify coverage.

IMPORTANT SAFETY INFORMATION (CONT)

Warnings and Precautions (cont)

Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.

Risk of Joint Cartilage Necrosis and Degeneration with Unapproved Intra-articular Use: Animal studies evaluating the effects of ZYNRELEF following intra-articular administration in the knee joint demonstrated cartilage necrosis and degeneration.

Chondrolysis: Limit exposure to articular cartilage due to the potential risk of chondrolysis.

Methemoglobinemia: Cases have been reported with local anesthetic use.

Serious Skin Reactions: NSAIDs, including meloxicam, can cause serious skin adverse reactions. If symptoms present, evaluate clinically.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): If symptoms are present, evaluate clinically.

Fetal Toxicity: Due to the risk of oligohydramnios/fetal renal dysfunction and premature closure of the ductus arteriosus with NSAIDs, limit use of ZYNRELEF between about 20 to 30 weeks gestation, and avoid use after about 30 weeks.

Hematologic Toxicity: Monitor hemoglobin and hematocrit in patients with any signs or symptoms of anemia.

Drug Interactions

Drugs That Interfere with Hemostasis: Monitor patients for bleeding who are using ZYNRELEF with drugs that interfere with hemostasis (eg, warfarin, aspirin, SSRIs/SNRIs).

ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), or Beta-Blockers: Use with ZYNRELEF may diminish the antihypertensive effect of these drugs. Monitor blood pressure.

ACE Inhibitors and ARBs: Use with ZYNRELEF in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function.

Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects.

See Important Safety Information throughout and full [Prescribing Information](#), including [Boxed Warning](#).

ACUTE CARE (HOSPITAL INPATIENT DEPARTMENT, ED^a, AND HOPD) COVERAGE AND BILLING FOR ZYNRELEF

Coverage for ZYNRELEF varies by health insurance plan and site of care. Reimbursement of ZYNRELEF in a surgical procedure occurring during a hospital inpatient admission would be included in the diagnosis-related group (DRG) payment.

The table below summarizes the coverage and payment type for HOPDs.

ZYNRELEF Coverage and Reimbursement Policy in HOPDs

Medicare	ZYNRELEF is reimbursed separately through 2027 . Through March 2025: Separate reimbursement at ASP + 6% (<i>pass-through status</i>). Effective April 1, 2025: ZYNRELEF is covered under the Non Opioid Policy for Pain Relief. The Policy provides separate payments for qualifying non-opioid treatments for pain relief in both the hospital outpatient department and ambulatory surgical center settings. The goal of this policy is to remove financial barriers to use non-opioids and ensure the use of opioids is not financially incentivized.
Medicaid	Each State Medicaid Agency sets its own coverage policies and payment rates.
Private Commercial Payer	Separate payment for ZYNRELEF is available for many commercial patients. Commercial reimbursement varies by payer and site of care; contact payers to verify coverage.

^aFor patients covered by Medicare, when the surgery occurs in the ED, reimbursement is the same as in a HOPD; however, if a patient is admitted, inpatient reimbursement rules apply.

IMPORTANT SAFETY INFORMATION (CONT)

Use in Specific Populations

Infertility: NSAIDs are associated with reversible infertility. Consider avoidance of ZYNRELEF in women who have difficulties conceiving.

Severe Hepatic Impairment: Only use if benefits are expected to outweigh risks; monitor for signs of worsening liver function.

Severe Renal Impairment: Not recommended.

Adverse Reactions

Most common adverse reactions (incidence $\geq 5\%$) in controlled clinical trials with ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.

Report side effects to Heron at 1-844-437-6611 or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See Important Safety Information throughout and full [Prescribing Information](#), including [Boxed Warning](#).

SAMPLE CLAIM FORM CMS-1450 (UB-04): HOPD, ASC (NON-MEDICARE PAYERS; CONFIRM WITH PAYER)

Complete the information needed to bill for the procedure. **ZYNRELEF must be billed using a separate line.**

Field 42: Include revenue code 0636.

Field 43: Include the required additional information (eg, product name and NDC).

Example:

- For 200 mg/6 mg (7 mL) VVS kit: ZYNRELEF, 47426-303-01
- For 400 mg/12 mg (14 mL) VAN kit: ZYNRELEF, 47426-501-02
- For 200 mg/6 mg (7 mL) VAN kit: ZYNRELEF, 47426-503-01

Payer NDC requirements and placement may vary; confirm with payer or Heron Connect.

Field 44: Specify HCPCS Code for ZYNRELEF, **C9088**.

To indicate that the complete single-dose vial was administered, use the HCPCS modifier JZ.^a

If a portion of the single-use vial was discarded, document it on a separate line using the HCPCS modifier JW.

Commercial: Confirm coding with payers or by contacting Heron Connect.

Field 46: Specify the number of units administered. **The billable unit for C9088 is 1 mg/0.03 mg.** For example, 400 mg/12 mg (14 mL) corresponds to 400 billable units.

^aFor dates of service on or after July 1, 2023, the JZ modifier is required on claims for single-dose containers when no amount was discarded.

1		2		3a PAT CNTL #		4 TYPE OF BILL	
3b ICDT REC #		5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM		7	
8 PATIENT NAME				9 PATIENT ADDRESS			
10 BIRTHDATE		11 SEX		12 DATE		13 ADMISSION 13 HR	
14 TYPE		15 SRC		16 DHR		17 STAT	
18		19		20		21	
22		23		24		25	
26		27		28		29 ACCT STATE	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	

SAMPLE CLAIM FORM CMS-1500: ASC (MEDICARE) AND PHYSICIAN OFFICE

CMS requires ASCs to submit a CMS-1500 claim form when billing a Medicare Administrative Contractor (MAC). Most commercial plans require a CMS-1450 (UB-04) claim form (see page 6 for an example). Please use the claim form that you are currently utilizing when submitting to a commercial plan. Physician office billing requires the submission of the CMS-1500 claim form for all plans.

Complete the information needed to bill for the procedure. **ZYNRELEF must be billed using a separate line.**

Field 24 (Shaded Area):

Include the required additional information (eg, product name and NDC).

Example:

- For 200 mg/6 mg (7 mL) VVS kit: ZYNRELEF, 47426-303-01
- For 400 mg/12 mg (14 mL) VAN kit: ZYNRELEF, 47426-501-02
- For 200 mg/6 mg (7 mL) VAN kit: ZYNRELEF, 47426-503-01

Payer NDC requirements and placement may vary; confirm with payer or Heron Connect.

Field 24D: Specify HCPCS Code for ZYNRELEF, **C9088**.

To indicate that the complete single-dose vial was administered, use the HCPCS modifier JZ.^a

If a portion of the single-use vial was discarded, document it on a separate line using the HCPCS modifier JW.

Additional modifiers may be required, please confirm with commercial plans.

Field 24G:

Specify the number of units administered. **The billable unit for C9088 is 1 mg/0.03 mg.** For example, 400 mg/12 mg (14 mL) corresponds to 400 billable units.

^aFor dates of service on or after July 1, 2023, the JZ modifier is required on claims for single-dose containers when no amount was discarded.



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA BLK/LUNG OTHER (Medicare#) (Medicaid#) (ID#/DxID#) (Member ID#) (ID#) (ID#)												16. INSURED'S ID, NUMBER (For Program in Item 1)	
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)						3. PATIENT'S BIRTH DATE MM DD YY			SEX M <input type="checkbox"/> F <input type="checkbox"/>		4. INSURED'S NAME (Last Name, First Name, Middle Initial)		
5. PATIENT'S ADDRESS (No., Street)						6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>			7. INSURED'S ADDRESS (No., Street)			8. RESERVED FOR NUCC USE	
CITY				STATE		CITY				STATE			
ZIP CODE				TELEPHONE (Include Area Code)		ZIP CODE				TELEPHONE (Include Area Code)			
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)						10. IS PATIENT'S CONDITION RELATED TO: a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO			11. INSURED'S POLICY GROUP OR FECA NUMBER				
a. OTHER INSURED'S POLICY OR GROUP NUMBER						b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO			12. INSURED'S DATE OF BIRTH MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>		
b. RESERVED FOR NUCC USE						c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO			13. OTHER CLAIM ID (Designated by NUCC)				
c. RESERVED FOR NUCC USE						10c. CLAIM CODES (Designated by NUCC)			14. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO <i>If yes, complete items 9, 9a, and 9d.</i>				
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.												13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize payment of medical benefits to the undersigned physician or supplier for services described below.	
SIGNED _____ DATE _____						SIGNED _____							
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY						15. OTHER DATE QUAL. MM DD YY			16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY				
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE						17a. QUAL. 17b. NPI			18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY				
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)													
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY. Relate A-L to service line below (24E) ICD-10 A. _____ B. _____ C. _____ D. _____ E. _____ F. _____ G. _____ H. _____ I. _____ J. _____ K. _____ L. _____													
22. RESUBMISSION CODE ORIGINAL REF. NO.													
23. PRIOR AUTHORIZATION NUMBER													
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS OF UNITS H. EPSTI (Plan) I. ID. QUAL. J. RENDERING PROVIDER ID, #													
1 MM DD YY MM DD YY XX XXXX A XXX XX 1 NPI XXXXXXXXXXXX													
2 ZYNRELEF, [NDC] C9088 JZ A XXX XX XXX NPI XXXXXXXXXXXX													
3													
4													
5													
6													
25. FEDERAL TAX ID, NUMBER SSN EIN				26. PATIENT'S ACCOUNT NO.		27. ACCEPT ASSIGNMENT? (For gov't claims, see back) YES NO		28. TOTAL CHARGE \$		29. AMOUNT PAID \$		30. Rev'd for NUCC Use	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREE(S) OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)													
32. SERVICE FACILITY LOCATION INFORMATION													
33. BILLING PROVIDER INFO & PH # ()													
SIGNED _____ DATE _____						SIGNED _____							

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

This document is provided for your guidance only. Coding requirements may vary by payer; please consult the payer to determine which codes are required.

ZYNRELEF[®]
(bupivacaine and meloxicam)
extended-release solution,
for instillation use
29.25 mg/mL and 0.88 mg/mL

C9088

CLAIM SUBMISSION CHECKLIST

Have you included the HCPCS code for ZYNRELEF?

C9088

Have you included the following information to support utilization of C9088?

Drug name NDC

Have you utilized the appropriate modifier to document use of the complete single-dose vial (JZ) or to document that a portion of the vial was discarded (JW)?

Yes

Have you included other modifiers as applicable, such as TB or JG for drugs acquired through the 340B Program?

Yes

For billing and coding questions, call **Heron Connect**[®] at **1-844-HERON11 (1-844-437-6611)**
8 AM to 5 PM ET, Monday through Friday.

For more information, visit **HeronConnect.com**

Please see full Prescribing Information, including Boxed Warning.